Published in final edited form as:

Arch Immunol Ther Exp (Warsz). 2012 June ; 60(3): 173–181. doi:10.1007/s00005-012-0171-4.

The Role and Regulation of mTOR in T Lymphocyte Function

Thomas F. O'Brien^{1,2} and Xiao-Ping Zhong^{1,2}

¹Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA

²Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA

Abstract

The conversion of naïve T cells into effector T cells is initiated by stimulation through the T cell receptor (TCR). Upon activation, T cells undergo significant morphological and functional changes, putting new metabolic demands on the cell. Past research has identified the mammalian target of rapamycin (mTOR) as a critical regulator of cell metabolism, and the development of new genetic models has begun to reveal an important role for this pathway in the homeostasis and function of T lymphocytes. In this review we focus on the most recent findings that demonstrate the ability of the mTOR to regulate T cell activation, CD8⁺ memory cell formation and function, and helper T lineage differentiation. We highlight the importance of tight control of mTOR signaling by the tuberous sclerosis complex 1 for T cell homeostasis. Finally, we discuss the regulation of mTOR signaling by diacylglycerol kinases and the RasGRP1-Ras-Erk1/2 pathway in the context of TCR signaling.

Keywords

mammalian target of rapamycin; tuberous sclerosis complex 1; diacylglycerol kinase; RasGPP1; PI3K/Akt; T lymphocyte

Introduction

The mammalian target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine kinase that can simultaneously integrate multiple signaling inputs, including nutrients, amino acids, growth factors, and cytokines, to regulate cell metabolism, proliferation, and growth (Fingar and Blenis 2004; Stanfel et al. 2009; Wullschleger et al. 2006). The mTOR protein associates with a variety of proteins, and is a component of two unique signaling complexes referred to as mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). In mTORC1, mTOR associates with Raptor, and is sensitive to acute rapamycin treatment, while in mTORC2, mTOR is in complex with Rictor, and is less sensitive to acute rapamycin treatment (Kim and Sabatini 2004; Sarbassov et al. 2004). mTORC1 is activated by the GTP bound form of Ras homolog enriched in brain (Rheb). The tuberous sclerosis complex (TSC), a heterodimer consisting of hamartin (Tuberous sclerosis 1; TSC1) and tuberin (Tuberous sclerosis 2; TSC2), functions as an inhibitor of mTOR by inactivating Rheb (Huang and Manning 2009). At the present time, the relationship between the TSC complex and mTORC2 is not well understood.

The TSC complex was originally identified as a critical regulator of mammalian cell homeostasis in patients bearing disruptive genetic mutations in the TSC1 and/or TSC2 gene.

Corresponding author: Xiao-Ping Zhong, MD, PhD, Department of Pediatrics-Allergy and Immunology, Rm 133 MSRB, Research Drive, Box 2644, Duke University Medical Center, Durham, NC 27710, USA, Phone: 919-681-9450, Fax: 919-668-3750, zhong001@mc.duke.edu.

Functioning as a tumor repressor, mutations in either gene often result in large non-malignant tumors that can affect the brain, eyes, kidneys, pancreas, and pulmonary system. While the tumors are benign, they often interfere with normal organ function due to their large size, which can encroach on and compact vital organs in the area. The most important mechanistic insight into how the TSC complex functions in normal cell homeostasis and function came when Rheb was identified as the target of the GAP domain found in TSC2 (Garami et al. 2003; Inoki et al. 2002). Determining the structural motifs present on TSC1 and TSC2 has given researchers insight into the regulation and function of these molecules. Sequence analysis has revealed a multiple phosphorylation sites on TSC2 in addition to its GAP domain. These target residues on TSC2 can be phosphorylated by a number of upstream kinases including Amp-activated protein kinase (AMPK), Akt, and Erk. The variety of kinases that target TSC2 indicate a central role for the TSC complex in the context of nutrient metabolism and signaling. While TSC2 has been the focus of significant structure-function research, the same cannot be said for TSC1. The most well described domain within the TSC1 protein is its TSC2 binding motif. TSC1 has also been shown to be a binding partner of multiple proteins, and could serve as a protein scaffold that dictates the sub-cellular localization of its enzymatic partner TSC2.

Biochemical analysis has revealed that the TSC-mTOR signaling axis is downstream of several well known signaling pathways. Work done primarily in cell lines has established the PI3K/Akt pathway as being a positive regulator of the mTOR pathway. In response to growth factors Akt phosphorylates TSC2, which leads to the disruption of the TSC1-TSC2 complex. The dissociation of the TSC complex leads to the activation of Rheb and mTORC1 (Cai et al. 2006; Inoki et al. 2002; Ma et al. 2005). TSC2 can also be phosphorylated by Erk, which inactivates the complex (Ma et al. 2005). Indeed, investigators have demonstrated that the mTOR pathway is robustly activated subsequent to T cell receptor (TCR) and diacylglycerol (DAG) stimulation (Gorentla et al. 2011). In addition to the mTOR pathway being activated by the presence of extracellular stimuli, it is also regulated by intracellular energy reserves. AMPK is activated in response to low levels of intracellular ATP. During times of nutrient deprivation, AMPK directly phosphorylates TSC2, which promotes the GAP activity of the TSC complex, ultimately resulting in the inhibition of mTORC1 (Inoki et al. 2003).

The consideration of mTOR as a master regulator of cell metabolism comes from its capacity to control protein translation at a very fundamental level. As opposed to activating a few transcription factors that regulate a very specific set of genes, mTOR phosphorylates proteins that regulate the cell's translational machinery itself. As a component of two distinct signaling complexes, mTOR signaling proceeds through a number of downstream effector molecules. mTORC1 phosphorylates both the 70-kDa ribosomal S6 kinase (S6K1) and the translational repressor 4 elongation factor-binding protein 1 (4E-BP1) (Fingar et al. 2002). Once activated, S6K1 phosphorylates S6 (Jeno et al. 1988). It has been traditionally thought that phosphorylated S6 serves to promote mRNA translation, which include elongation factors and elements of the ribosomal translation machinery. In this way signaling through S6K is considered to promote protein translation in general by regulating the construction of the cell's translational machinery (Jefferies et al. 1994, 1997; Terada et al. 1994). Like S6K1, 4E-BP1 is a direct target of phosphorylation by mTORC1 and controls protein translation. 4E-BP1 acts as a repressor of translation by inhibiting the translation initiation factor eIF4E. Once phosphorylated by mTORC1, 4E-BP1 dissociates from eIF4E, where it can then initiate CAP-dependant translation (Gingras et al. 2001).

While the identification of rapamycin as a potent inhibitor of mTORC1 signaling has provided us with an invaluable tool to study the mechanisms that control mTORC1 signaling, no such reagent has been available to study the regulation of signaling exclusively

associated with mTORC2. As a result, identifying the upstream regulators of mTORC2 has proven more challenging. Recent findings have shown that the TSC complex can directly associate with and regulate mTORC2 in an mTORC1 independent manner (Huang et al. 2008). Investigators have also demonstrated that mTORC2 is regulated by mTORC1 activity. Specifically, S6K1 can phosphorylate Rictor *in vitro* and *in vivo*, which can then inhibit mTORC2 from phosphorylating its downstream target, Akt (Julien et al. 2010; Sarbassov et al. 2005). Phosphorylation of Akt at serine 473 has been used as the canonical readout of mTORC2 activity. It is interesting to note that Akt is a target of mTORC2 signaling, but also potently activates mTORC1. This logical sequence might suggest that mTORC2 can activate mTORC1, however, S6K1 activity is not altered in an mTORC2 knockdown models (Delgoffe et al. 2011; Jacinto et al. 2004; Lee et al. 2010).

mTOR Kinase Activity Is Required for Helper T Lineage Differentiation

Because the differentiation of naïve CD4⁺ T cells is dependent on multiple signaling inputs, including TCR and cytokine stimulation, investigators hypothesized that the mTOR pathway may serve to integrate these signals to regulate the appropriate differentiation program of naïve CD4⁺ T cells. The development of cytokine skewing *in vitro* culture systems have allowed investigators to begin to define the extrinsic and intrinsic signaling determinants that are involved in T helper lineage differentiation. To date, the T helper cells can be broadly differentiated into 4 distinct cell types, each with unique functional properties. These cells have come to be known as the T_h1, T_h2, T_h17, and T_{reg} lineages and are largely defined by the cytokines they secrete in response to antigen receptor stimulation.

The first two lineages identified were the T_h1 and T_h2 subsets. T_h1 CD4⁺ T cells have been shown to be important for the control of pathogens such as *Toxoplasma gondii* and *Leishmania major*. The ability of these T_h1 cells to control infection is, in part, reliant on their ability to produce large amounts of IFN- γ (Szabo et al. 2002). T_h2 cells are noted for their ability to produce IL-4, which mediates allergic responses and protection from parasitic infection. T-bet and GATA-3 were identified as T_h1 and T_h2 lineage specific transcription factors, respectively (Ouyang et al. 1998; Szabo et al. 2002). While the existence of the T_h1 and T_h2 lineages has been established for some time, the emergence of a new lineage became evident during studies experimental autoimmune encephalitis (EAE). From this model the T_h17 lineage emerged and was defined as IL-17 producing CD4⁺ T cells (Cua et al. 2003; Murphy et al. 2003). Like the T-bet in T_h1 and GATA-3 in T_h2 differentiation, ROR γ t was identified as a lineage specific transcription factor for T_h17 cells. The importance of ROR γ t in the differentiation of IL-17 producing CD4⁺ T cells, and in the progression of autoimmune inflammation has been extensively studied. ROR γ t deficient mice exhibit impaired T_h17 differentiation and are resistant to the induction of EAE (Chen et al. 2007).

In a model of mTOR inactivation, Delgoffe and colleagues generated a conditional mTOR deletion model, where the mTOR protein was specifically ablated in the T cell lineage (Delgoffe et al. 2011). *In vitro* differentiation cultures and *in vivo* immunizations revealed that mTOR signaling has a profound influence on T cell effector differentiation. Specifically, mTOR deficient T cells fail to differentiate into the T_h1, T_h2, and T_h17 lineages, which is associated with the inability to up-regulate the lineage specific transcription factors. Furthermore, the failure of mTOR deficient T cells to differentiate into the effector lineages was balanced by their differentiation into Foxp3⁺ regulatory T cells. In complementary studies, conditional deletion models of Rheb and Rictor in T cells defined the contributions of mTORC1 and mTORC2, respectively, in CD4⁺ T cell differentiation. In one study, mTORC1 proved to be crucial for the differentiation of the T_h1 and T_h17 lineages (Delgoffe et al. 2011), while another study demonstrated the importance of mTORC2 in T_h1 and T_h2 differentiation (Lee et al. 2010). The generation of new models designed to

investigate the specific contributions of components of the TSC-mTOR pathway will undoubtedly provide us with a clearer picture of this pathway's importance in helper T cell differentiation, and may help to pinpoint potential targets to improve T cell mediated immunity *in vivo*.

Negative Regulation of CD8⁺ Memory T Cell Development by mTOR

A successful T cell immune response is characterized by two distinct phases. The first is the exponential expansion of antigen specific T cells after infection. This massive phase of expansion ensures that there are enough effector cells to efficiently combat a spreading infection. Once the infection is resolved, the antigen specific T cell pool undergoes a period of contraction, following which only 5–10% of the antigen specific T cell pool will remain. These remaining cells are commonly referred to as the memory T cell pool. The second phase of the T cell immune response is the re-exposure of antigen to the resting memory T cell pool. Upon re-exposure to antigen, the memory T cell pool will re-expand, produce cytokines, and effector molecules more aggressively than a naive T cell pool with the same antigenic specificity. Memory T cells represent a distinct T cell population, and possesses properties not associated with conventional naïve T cells. They highly express the IL-7 receptor and the survival protein Bcl-2. The expression of the IL-7 receptor and Bcl-2 contribute to self-renewal potential unique to memory T cells. (Williams and Bevan 2007).

The primary expansion of a pathogen reactive T cell clone, and its contraction into a functional memory pool places these cells under extreme metabolic pressures. Given the data indicating that the differentiation of CD4⁺ T cells into effector and regulatory lineages is largely dependent on a functional mTOR signaling pathway, investigators hypothesized that the mTOR pathway may also play a crucial role in the formation of a functional CD8⁺ T cell memory pool. A recent report demonstrates that when used in low doses, rapamycin can enhance different aspects of memory T cell formation (Araki et al. 2009). When rapamycin is administered during the primary expansion phase of the T cell response, an increased CD8⁺ T cell memory pool was formed after lymphocytic choriomeningitis virus (LCMV) infection. When the mTOR inhibitor was administered during the contraction phase, the conversion from effector to memory cell was expedited. Furthermore, the memory CD8⁺ T cells formed in the presence of rapamycin were more effective at controlling viral replication. In the same study the investigators established a cell intrinsic role for components of the mTOR in repressing memory T cell formation by retrovirally delivering RNAi constructs against mTOR into LCMV specific P14⁺ CD8⁺ T cells before adoptive transfer. In another study, IL-12 was shown to activate the mTOR pathway and the T_H1 transcription factor T-bet, leading to the generation of effector T cells. However, when stimulated in the presence of rapamycin, OT-I CD8⁺ T cells exhibited curtailed expression of T-bet, and enhanced expression of eomesodermin (Rao et al. 2010). Previous reports have shown a positive correlation between eomesodermin expression and precursor memory CD8⁺ T cell formation (Intlekofer et al. 2005), suggesting that mTOR signaling may directly influence the expression of transcription factors that dictate memory versus effector lineage decisions. In addition, expression of CCR7 and CD62L in central memory T cells is important for homing of these cells to lymph nodes. Since mTOR inhibits CCR7 and CD62L expression, it is possible that mTOR may also control memory T cells by influencing their migratory potential (Sinclair et al. 2008). Finally, TRAF-6 deficient T cells can develop into effector T cells, but fail to differentiate into memory T cells (Pearce et al. 2009). This study demonstrated that TRAF-6 deficient T cells exhibited lower AMP kinase activity, an inhibitor of mTOR. They showed, however, that the formation of memory T cells could be restored by treating the cells with metformin, an AMPK agonist. Treating the T cells with metformin activated AMP kinase and inhibited mTOR pathway activation.

Cumulatively, these results strongly suggest that the development of memory T cells is strongly inhibited by mTOR signaling. Presently, the mechanism by which mTOR inhibits memory T cell differentiation remains undefined. These studies also revealed a previously unappreciated function for rapamycin. Generally considered an immunosuppressant, rapamycin's ability to promote memory T cell formation and function may provide clinicians a new tool to enhance the effectiveness of vaccines.

Dys-Regulation of the TSC-mTOR Pathway Impacts T Cell Homeostasis

In general, T cells can be thought to exist in two different states: naïve and activated. Naïve T cells are quiescent and are characterized by minimal metabolic activity. T cells become activated in response to TCR antigens and cytokines, which require an anabolic metabolism program that will support T cell proliferation and protein synthesis. In this way T cell metabolism and homeostasis are intimately related. As an established regulator of cell metabolism, investigators have hypothesized that mTOR kinase activity may play a critical role for T cell homeostasis and function.

The original insights into the importance of the mTOR pathway in T cell biology emerged from *in vitro* cell cultures that included rapamycin. While rapamycin had been identified as a potent immunosuppressant, the mechanisms by which it imposed its inhibitory capacity on mammalian T cells remained unclear for many years. Initial findings showed that rapamycin inhibited the ability of T cells to proliferate in response to IL-2, but not their ability to produce IL-2. These studies also showed that rapamycin can induce anergy in CD4⁺ T cells even in the presence of co-stimulation. T cells anergized in the presence of rapamycin exhibit decreased MAPK pathway activity as well as a block from the G1 to S phase of cell cycle by inhibiting cyclin D3 expression (Dumont et al. 1990; Powell et al. 1999; Zheng et al. 2007). This data led investigators to believe that entry into cell cycle was largely responsible for the prevention of T cell anergy. Recent studies have shown, however, that the activation of the mTOR pathway itself can initiate the reversal of anergy, as opposed to entry into cell cycle (Allen et al. 2004; Colombetti et al. 2002; Zheng et al. 2007).

While experiments using rapamycin represent loss-of-function studies, only recently have gain-of-function models emerged to assess the consequence of hyper-activation of the TSC-mTOR pathway in T cells. In particular, the generation of a mouse model where TSC1 is genetically deleted exclusively in the T cell lineage. Using this model, our group and others have demonstrated that TSC1 inhibits mTORC1 activity, but promotes mTORC2 signaling in T cells. TSC1-deficient T cells exhibit highly phosphorylated S6K1 and decreased phosphorylation of Akt and its downstream targets (O'Brien et al. 2011; Yang et al. 2011). In HEK293 cells, it has been demonstrated that Rictor, a component of mTORC2, is directly phosphorylated at Thr1135 by S6K1 after growth factor stimulation, and that this phosphorylation is sensitive to rapamycin. In cells that express a Rictor T1135A mutant, which cannot be phosphorylated by S6K1, mTORC2 dependant Akt phosphorylation was markedly increased, strongly suggesting that mTORC1 activation can directly suppress mTORC2 activity (Julien et al. 2010). Whether or not the regulation of mTORC2 by mTORC1, through S6K1 and Rictor, is physiologically relevant during the activation of primary T cells remains to be determined.

In addition to the signaling abnormalities in TSC1-deficient T cells, our research revealed that constitutive mTOR activation via TSC1-deficiency results in a smaller peripheral T cell pool and impaired T cell survival. The impaired phosphorylation of Akt by mTORC2 after TCR stimulation in TSC1-deficient T cells led us to hypothesize that ectopic expression of a constitutively active Akt construct in the absence of TSC1 may rescue the apoptotic phenotype. Expression of Akt-DD, a construct that mimics an Akt molecule that has been

phosphorylated by PDK1 and mTORC2, could rescue the increased cell death observed in TSC1-deficient CD4⁺ and CD8⁺ T cells. Interestingly, the increased cell death cannot be rescued when TSC1-deficient T cells are retrovirally transfected with Akt-S473D, which mimics the activity of Akt phosphorylated exclusively by mTORC2 (O'Brien et al. 2011). Since only expression of Akt-DD but not Akt-S473D can rescue these cells from death, it suggests that the increased death of TSC1-deficient T cells could not be solely due to decreased mTORC2 activity. The lack of survival defects in Rictor-deficient T cells also supports that mTORC2 is not essential for T cell survival (Lee et al. 2010). Aside from decreased mTORC2-Akt activity, increased mTORC1 signaling has been reported to promote cell death. In hepatocyte cell lines, S6K1-deficiency led to down-regulation of caspase-8, caspase-3 activation, cytochrome c release, and protected against the onset of apoptosis (Gonzalez-Rodriguez et al. 2009). Since rapamycin cannot rescue TSC1-deficient T cells from death, enhanced mTORC1 may not directly cause death of these cells. However, this result does not completely rule out a role of increased mTORC1 activity in the death of TSC1 deficient T cells. The death prone property of TSC1-deficient T cells could be caused by a chronic increase of mTORC1 signaling, which could program these cell to a pro-death fate that could not be reverted by acute rapamycin treatment.

It is known that reactive oxygen species (ROS) are a byproduct of cellular respiration and cause mitochondrial damage resulting in the death of activated T cells (Hildeman et al. 1999). TSC1-deficient T cells display increased ROS production, but decreased mitochondrial content, number, and membrane potential, all of which are coincident with their apoptotic phenotype. Evidence generated in our lab demonstrates that *N*-acetylcysteine, an ROS scavenger, can reduce the death of TSC1-deficient T cells and can increase mitochondrial membrane potential *in vitro*, suggesting that TSC1 may promote T cell survival mainly through the inhibition of ROS production to maintain mitochondrial integrity. Of note, CD28 mediated co-stimulation, but not rapamycin treatment, can reduce TSC1-deficient T cell death correlated with reduced ROS production and increased mitochondrial potential, but without obvious increase of Akt activity. Thus, TSC1 may inhibit ROS production in T cells and promote T cell survival through mTOR-independent mechanisms. Further studies are needed to determine the mechanisms by which TSC1 regulates ROS production and mitochondrial homeostasis.

The conversion of a naïve T cell into an effector cell is coordinate with fundamental changes in T cell metabolism. During times of activation, T cells rely on energy produced during glycolysis, even in oxygen rich environments. In accordance with an activated T cell's need to grow in size, replicate, and produce cytokines the cell switches from a catabolic to anabolic metabolism profile. Past research has established the TSC-mTOR pathway as a critical regulator of glycolysis and an important interpreter of extracellular signaling determinants. Since T cell activation requires such a dramatic change in their metabolic profile, investigators have recently hypothesized that proper regulation of the TSC-mTOR pathway may play a crucial role in maintaining naïve T cell quiescence *in vivo*. While it is an area of intense study, naïve T cell quiescence is still poorly understood, with several transcription factors being implicated as active enforcers of T cell quiescence (Kuo et al. 1997; Modiano et al. 2008; Yusuf and Fruman 2003). In order to address the relationship between the TSC-mTOR pathway activation and naïve T cell quiescence *in vivo*, the conditional TSC1 T cell model was utilized. Both our group and others found that the deletion of TSC1 in T cells resulted in enlarged cells. Furthermore, by using the DNA incorporating nucleotide BrdU, TSC1-deficient T cells had actively entered cell cycle, whereas wild-type naïve T cells were not actively synthesizing new DNA (O'Brien et al. 2011; Yang et al. 2011; Wu et al. 2011). These TSC1-deficient T cells also displayed the effector memory T cell phenotype of CD44^{hi}CD62L^{lo}, which was at the expense of the naïve quiescent CD44^{lo}CD62L^{hi} population. It is not currently understood whether the up-

regulated CD44 expression is controlled directly by the TSC-mTOR pathway, or if it is a secondary result of enhanced homeostatic T proliferation in the TSC1^{f/f}-CD4-Cre mice, which exhibit pronounced T cell lymphopenia. This phenomenon could be addressed by adoptively transferring both wild-type and TSC1-deficient T cells into naïve wild-type recipient hosts, and in the complementary experiment, transferring wild-type and TSC1-deficient T cells into the TSC1^{f/f}-CD4-Cre mice.

In agreement with TSC1-deficient T cells entry into cell cycle as measured by BrdU incorporation *ex vivo*, a large scale genetic analysis revealed up-regulation of several cell cycle associated genes including cyclin A2 and cyclin B2 (Yang et al. 2011). Interestingly, this observed phenotype of hyper-proliferation in TSC1-deficient T cells somewhat conflicts with the reduced peripheral T cell pool. However, because of the enhanced cell death observed in these cells, investigators surmised that by crossing their TSC1 knockout lines to Bcl-2 transgenic mice may rescue the cell death phenotype. They observed that TSC1^{f/f}-CD4-Cre-Bcl2^{TG} mice had normal numbers of peripheral T cells and underwent apoptosis comparable to wild-type mice (Yang et al. 2011). As an anti-apoptotic molecule, Bcl-2 antagonized the activity of the pro-apoptotic molecule Bim, which was substantially up-regulated in TSC1-deficient T cells. Notably, the loss of quiescence in the TSC1^{f/f}-CD4-Cre mice was not restored when crossed to the Bcl-2 transgenic mice, indicating that the apoptotic program in TSC1-deficient T cells is not a causative factor in their non-quiescent phenotype. Additional experiments will be able to determine whether or not loss of quiescence leads to T cell apoptosis. While crossing the experimental mice to the Bcl-2 transgene rescued the apoptotic phenotype in TSC1-deficient T cells, mechanistic insights are not readily revealed because the addition of Bcl-2 into any pro-death program is typically viewed as a “cure-all” because of its far downstream role in the intrinsic cell death pathway. In our studies, rapamycin was unable to rescue T cell death, suggesting that the TSC complex inhibits cell death by a mechanism independent of mTORC1 activity. At the present time very little work has been done to determine the activity of the TSC complex independent of the mTOR kinase. Biochemical studies including co-immunoprecipitation and mass spectrometry could determine additional signaling partners for TSC1 and TSC2, and may provide valuable clues that would broaden our understanding of this tumor suppressor complex.

Given the aforementioned phenotype, investigators examined if the spontaneous conversion of quiescent TSC1-deficient T cells into cycling activated T cells affect their ability to mount an effective adaptive immune response *in vivo*. To investigate T cell expansion and cytokine production *in vivo*, TSC1^{f/f}-CD4-Cre mice were infected with Ovalbumin expressing *Listeria monocytogenes*. In response to bacterial infection, TSC1-deficient T cells showed impaired expansion and cytokine production, which could not be rescued by the introduction of the Bcl-2 transgene (Yang et al. 2011). We have shown that TSC1-deficiency in T cells does not globally affect TCR signaling. However, the heterogeneous expression of early T cell activation markers after *in vitro* stimulation with α -CD3 suggests that TSC1 modulates T cell activation, and that the enhanced mTORC1 activity in TSC1-deficient T cells regulates gene transcription associated with cytokine production. Because the TSC complex is an inhibitor of mTOR kinase activity, the TSC1^{f/f}-CD4-Cre model should served as the complementary model to the mTOR^{f/f}-CD4-Cre line. Interestingly, both models exhibit an impaired ability to respond to invading pathogens, suggesting that mTOR activity is neither “all good” nor “all bad,” but that an intermediate amount of activity is appropriate for normal T cell responses *in vivo*. Determining the optimal window of mTOR kinase activity to mount a T cell immune response will be a critical focus in this particular area of study.

mTOR Kinase Activity Is Regulated by Signaling Events Proximal to the TCR

The engagement of the TCR initiates a variety of changes within a T cell. Among those changes are increase in size, proliferative capacity, and new protein synthesis. TCR signaling results in the production of secondary messengers, which serve to amplify and direct unique signaling pathways in activated T cells. As one of those secondary messengers, DAG binds to and activates both RasGRP1 and protein kinase C θ (PKC θ) via their cysteine-rich C1 domains. The result of DAG binding to RasGRP1 and PKC θ is the activation of the RasGRP-Ras-Mek-Erk and PKC θ -IKK-NF- κ B pathways, respectively (Coudronniere et al. 2000; Dower et al. 2000; Ebinu et al. 2000; Isakov and Altman 2002; Sun et al. 2000; Tognon et al. 1998). The proximity of DAG production to the signaling events immediately downstream of the TCR, and its ability to activate multiple signaling pathways simultaneously, led investigators to hypothesize that the dys-regulation of DAG signaling and metabolism might perturb normal T cell homeostasis and function.

As a potent positive regulator of T cell activation, the termination of DAG signaling is necessary to limit damage mediated by perpetually activated T cells or the development of an autoreactive T cell pool. A family of enzymes, the DAG kinases (DGKs), converts DAG to phosphatidic acid (PA), effectively terminating DAG mediated signaling (Kazanietz 2002; Topham and Prescott 1999; van Blitterswijk and Houssa 2000; Zhong et al. 2008, 2011). In order to assess the functional relevance of DAG signaling in T cells *in vivo*, DGK-deficient mice were created, and analysis of DGK-deficient T cells revealed a variety of abnormalities. *In vitro*, DGK-deficient T cells show enhanced expression of the early T cell activation markers and are hyper-proliferative. *In vivo*, DGK-deficient T cells are resistant to anergy induction and respond more vigorously to LCMV infection (Olenchok et al. 2006a; Zhong et al. 2003). In addition, DGK α and ζ synergistically promote T cell maturation at least partially via generating PA (Guo et al. 2008). These observations demonstrate that DGKs serve to as signal switches by dampening DAG-mediated signaling and by initiating PA-mediated signaling. Such regulatory functions of DGKs are not limited to T cells as DGK ζ has been shown to regulate the function of other lineages in the immune system (Liu et al. 2007; Olenchok et al. 2006b; Zhong et al. 2011).

In non-T cell line models, both DGK- and phospholipase D-derived PA has been reported to bind to and increase mTOR signaling (Avila-Flores et al. 2005; Fang et al. 2001). In T cells, we surprisingly found that deficiency of both DGK α and ζ enhances both mTORC1 and mTORC2 signaling following TCR stimulation. Phorbol 12-myristate 13-acetate, a DAG mimic, stimulation induces strong mTORC1 and mTORC2 activation. Together these observations indicate that DGKs predominantly inhibit mTOR activation by terminating DAG. At present, it is unclear whether DGK-derived PA participates in mTOR activation in T cells. Studies using both loss- and gain-of-function studies on each molecule within the RasGRP-Ras-Mek1/2 pathway have demonstrated further that the RasGRP-Ras-Mek-Erk1/2 cascade functions as the downstream effector of DAG to activate both mTORC1 and mTORC2 in T cells (Gorentla et al. 2011). In contrast to mTORC1, the lack of a specific mTORC2 inhibitor has made the identification of upstream regulators of mTORC2 signaling more challenging. Work from our group has demonstrated, for the first time in T cells, that RasGRP1, Ras, and Mek function to promote mTORC2 signaling in response to TCR stimulation. Specifically, RasGRP-deficient thymocytes exhibit impaired mTORC2 signaling, while the phosphorylation of Akt (S473) was enhanced in thymocytes expressing a constitutively active Ras allele after TCR stimulation (Gorentla et al. 2011). In non-T cell lines, Erk1/2 can directly phosphorylate TSC2, leading to the dissociation of the TSC complex, and the activation of the mTORC1 pathway (Ma et al. 2005). It remains to determine whether the RasGRP1-Ras-Erk1/2 pathway functions in a similar manner to

promote mTORC1 activation in T cells and how this pathway leads to mTORC2 activation. These studies highlight a crucial role for DGK-mediated DAG metabolism in the activation of the mTOR pathway in response to TCR stimulation and has allowed for the construction of a conceptual signaling model connecting DAG metabolism and mTOR kinase activity (Fig. 1). The identification of the RasGRP1-Ras-Erk1/2 pathway as critical activator of mTOR signaling also raises the possibility of abnormal mTOR signaling may contribute to the impairment of T cell maturation and activation caused by dysregulation of this pathway (Dower et al. 2000; Shen et al. 2011a, 2011b).

Concluding Remarks

The mechanisms underlying the T cell receptor's ability to influence gene transcription has been the primary focus of T cell biologists for the past 40 years. In physiological settings, T cells encounter antigen in secondary lymphoid organs that are replete with nutrients, growth factors, and cytokines. How the T cell integrates these environmental cues with the signals emanating from the TCR is not well understood, and has become an area of intense research. Recent work has demonstrated the ability of mTOR to translate the extracellular signals present in an activated T cell's microenvironment into a T cell differentiation program specifically suited to control a burgeoning infection. To date, the most definitive studies examining the role of mTOR in T cell function come from a conditional model of mTOR gene deletion in T cells. The generation of tissue specific models that target other components of the TSC-mTOR pathway, and the identification of new mTOR kinase substrates will further serve to connect the TCR signal with T cell metabolism and function. Finally, improving the understanding of mechanisms that regulate mTOR signaling should provide novel strategies to manipulate mTOR activity for treatment of autoimmune diseases and cancer.

Acknowledgments

We thank Dr. Balachandra Gorentla for his helpful discussions regarding this work and Sruti Srivatsan for helpful discussions and editing the manuscript. This study is supported by funding from the National Institute of Health (R01AI076357, R01AI079088, and R21AI079873), the American Cancer Society (RSG-08-186-01-LIB), and the American Heart Association.

References

- Allen A, Zheng Y, Gardner L, et al. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. *J Immunol.* 2004; 172:4797–4803. [PubMed: 15067056]
- Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. *Nature.* 2009; 460:108–112. [PubMed: 19543266]
- Avila-Flores A, Santos T, Rincon E, et al. Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid. *J Biol Chem.* 2005; 280:10091–10099. [PubMed: 15632115]
- Cai SL, Tee AR, Short JD, et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. *J Cell Biol.* 2006; 173:279–289. [PubMed: 16636147]
- Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. *Semin Immunol.* 2007; 19:400–408. [PubMed: 18166487]
- Colombetti S, Benigni F, Basso V, et al. Clonal anergy is maintained independently of T cell proliferation. *J Immunol.* 2002; 169:6178–6186. [PubMed: 12444122]
- Coudronniere N, Villalba M, Englund N, et al. NF-kappa B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta. *Proc Natl Acad Sci USA.* 2000; 97:3394–3399. [PubMed: 10716728]

- Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. *Nature*. 2003; 421:744–748. [PubMed: 12610626]
- Delgoffe GM, Polizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. *Nat Immunol*. 2011; 12:295–303. [PubMed: 21358638]
- Dower NA, Stang SL, Bottorff DA, et al. RasGRP is essential for mouse thymocyte differentiation and TCR signaling. *Nat Immunol*. 2000; 1:317–321. [PubMed: 11017103]
- Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. *J Immunol*. 1990; 144:251–258. [PubMed: 1688572]
- Ebinu JO, Stang SL, Teixeira C, et al. RasGRP links T-cell receptor signaling to Ras. *Blood*. 2000; 95:3199–3203. [PubMed: 10807788]
- Fang Y, Vilella-Bach M, Bachmann R, et al. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. *Science*. 2001; 294:1942–1945. [PubMed: 11729323]
- Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. *Oncogene*. 2004; 23:3151–3171. [PubMed: 15094765]
- Fingar DC, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. *Genes Dev*. 2002; 16:1472–1487. [PubMed: 12080086]
- Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. *Mol Cell*. 2003; 11:1457–1466. [PubMed: 12820960]
- Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. *Genes Dev*. 2001; 15:2852–2864. [PubMed: 11691836]
- Gonzalez-Rodriguez A, Alba J, Zimmerman V, et al. S6K1 deficiency protects against apoptosis in hepatocytes. *Hepatology*. 2009; 50:216–229. [PubMed: 19437488]
- Gorentla BK, Wan CK, Zhong XP. Negative regulation of mTOR activation by diacylglycerol kinases. *Blood*. 2011; 117:4022–4031. [PubMed: 21310925]
- Guo R, Wan CK, Carpenter JH, et al. Synergistic control of T cell development and tumor suppression by diacylglycerol kinase alpha and zeta. *Proc Natl Acad Sci USA*. 2008; 105:11909–11914. [PubMed: 18689679]
- Hildeman DA, Mitchell T, Teague TK, et al. Reactive oxygen species regulate activation-induced T cell apoptosis. *Immunity*. 1999; 10:735–744. [PubMed: 10403648]
- Huang J, Dibble CC, Matsuzaki M, et al. The TSC1–TSC2 complex is required for proper activation of mTOR complex 2. *Mol Cell Biol*. 2008; 28:4104–4115. [PubMed: 18411301]
- Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. *Biochem Soc Trans*. 2009; 37(Pt 1):217–222. [PubMed: 19143635]
- Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. *Nat Cell Biol*. 2002; 4:648–657. [PubMed: 12172553]
- Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. *Cell*. 2003; 115:577–590. [PubMed: 14651849]
- Intlekofer AM, Takemoto N, Wherry EJ, et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. *Nat Immunol*. 2005; 6:1236–1244. [PubMed: 16273099]
- Isakov N, Altman A. Protein kinase C(theta) in T cell activation. *Annu Rev Immunol*. 2002; 20:761–794. [PubMed: 11861617]
- Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. *Nat Cell Biol*. 2004; 6:1122–1128. [PubMed: 15467718]
- Jefferies HB, Fumagalli S, Dennis PB, et al. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. *EMBO J*. 1997; 16:3693–3704. [PubMed: 9218810]
- Jefferies HB, Reinhard C, Kozma SC, et al. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. *Proc Natl Acad Sci USA*. 1994; 91:4441–4445. [PubMed: 8183928]
- Jeno P, Ballou LM, Novak-Hofer I, et al. Identification and characterization of a mitogen-activated S6 kinase. *Proc Natl Acad Sci USA*. 1988; 85:406–410. [PubMed: 3257566]

- Julien LA, Carriere A, Moreau J, et al. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. *Mol Cell Biol.* 2010; 30:908–921. [PubMed: 19995915]
- Kazanietz MG. Novel "nonkinase" phorbol ester receptors: the C1 domain connection. *Mol Pharmacol.* 2002; 61:759–767. [PubMed: 11901214]
- Kim DH, Sabatini DM. Raptor and mTOR: subunits of a nutrient-sensitive complex. *Curr Top Microbiol Immunol.* 2004; 279:259–270. [PubMed: 14560962]
- Kuo CT, Veselits ML, Leiden JM. LKLF: A transcriptional regulator of single-positive T cell quiescence and survival. *Science.* 1997; 277:1986–1990. [PubMed: 9302292]
- Lee K, Gudapati P, Dragovic S, et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. *Immunity.* 2010; 32:743–753. [PubMed: 20620941]
- Liu CH, Machado FS, Guo R, et al. Diacylglycerol kinase zeta regulates microbial recognition and host resistance to *Toxoplasma gondii*. *J Exp Med.* 2007; 204:781–792. [PubMed: 17371930]
- Ma L, Chen Z, Erdjument-Bromage H, et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. *Cell.* 2005; 121:179–193. [PubMed: 15851026]
- Modiano JF, Johnson LD, Bellgrau D. Negative regulators in homeostasis of naive peripheral T cells. *Immunol Res.* 2008; 41:137–153. [PubMed: 18415030]
- Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. *J Exp Med.* 2003; 198:1951–1957. [PubMed: 14662908]
- O'Brien TF, Gorentla BK, Xie D, et al. Regulation of T-cell survival and mitochondrial homeostasis by TSC1. *Eur J Immunol.* 2011; 41:3361–3370. [PubMed: 21805467]
- Olenchock BA, Guo R, Carpenter JH, et al. Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. *Nat Immunol.* 2006a; 7:1174–1181. [PubMed: 17028587]
- Olenchock BA, Guo R, Silverman MA, et al. Impaired degranulation but enhanced cytokine production after Fc epsilonRI stimulation of diacylglycerol kinase zeta-deficient mast cells. *J Exp Med.* 2006b; 203:1471–1480. [PubMed: 16717114]
- Ouyang W, Ranganath SH, Weindel K, et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. *Immunity.* 1998; 9:745–755. [PubMed: 9846495]
- Pearce EL, Walsh MC, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. *Nature.* 2009; 460:103–107. [PubMed: 19494812]
- Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. *J Immunol.* 1999; 162:2775–2784. [PubMed: 10072524]
- Rao RR, Li Q, Odunsi K, et al. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. *Immunity.* 2010; 32:67–78. [PubMed: 20060330]
- Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. *Curr Biol.* 2004; 14:1296–1302. [PubMed: 15268862]
- Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science.* 2005; 307:1098–1101. [PubMed: 15718470]
- Shen S, Chen Y, Gorentla BK, et al. Critical roles of RasGRP1 for invariant NKT cell development. *J Immunol.* 2011a; 187:4467–4473. [PubMed: 21957144]
- Shen S, Wu J, Srivatsan S, et al. Tight regulation of diacylglycerol-mediated signaling is critical for proper invariant NKT cell development. *J Immunol.* 2011b; 187:2122–2129. [PubMed: 21775687]
- Sinclair LV, Finlay D, Feijoo C, et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. *Nat Immunol.* 2008; 9:513–521. [PubMed: 18391955]
- Stanfel MN, Shamieh LS, Kaerberlein M, et al. The TOR pathway comes of age. *Biochim Biophys Acta.* 2009; 1790:1067–1074. [PubMed: 19539012]
- Sun Z, Arendt CW, Ellmeier W, et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. *Nature.* 2000; 404:402–407. [PubMed: 10746729]

- Szabo SJ, Sullivan BM, Stemmann C, et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. *Science*. 2002; 295:338–342. [PubMed: 11786644]
- Terada N, Patel HR, Takase K, et al. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. *Proc Natl Acad Sci USA*. 1994; 91:11477–11481. [PubMed: 7972087]
- Tognon CE, Kirk HE, Passmore LA, et al. Regulation of RasGRP via a phorbol ester-responsive C1 domain. *Mol Cell Biol*. 1998; 18:6995–7008. [PubMed: 9819387]
- Topham MK, Prescott SM. Mammalian diacylglycerol kinases, a family of lipid kinases with signaling functions. *J Biol Chem*. 1999; 274:11447–11450. [PubMed: 10206945]
- van Blitterswijk WJ, Houssa B. Properties and functions of diacylglycerol kinases. *Cell Signal*. 2000; 12:595–605. [PubMed: 11080611]
- Williams MA, Bevan MJ. Effector and memory CTL differentiation. *Annu Rev Immunol*. 2007; 25:171–192. [PubMed: 17129182]
- Wu Q, Liu Y, Chen C, et al. The tuberous sclerosis complex-mammalian target of rapamycin pathway maintains the quiescence and survival of naive T cells. *J Immunol*. 2011; 187:1106–1112. [PubMed: 21709159]
- Wulschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. *Cell*. 2006; 124:471–484. [PubMed: 16469695]
- Yang K, Neale G, Green DR, et al. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. *Nat Immunol*. 2011; 12:888–897. [PubMed: 21765414]
- Yusuf I, Fruman DA. Regulation of quiescence in lymphocytes. *Trends Immunol*. 2003; 24:380–386. [PubMed: 12860529]
- Zheng Y, Collins SL, Lutz MA, et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. *J Immunol*. 2007; 178:2163–2170. [PubMed: 17277121]
- Zhong XP, Guo R, Zhou H, et al. Diacylglycerol kinases in immune cell function and self-tolerance. *Immunol Rev*. 2008; 224:249–264. [PubMed: 18759932]
- Zhong XP, Hainey EA, Olenchock BA, et al. Enhanced T cell responses due to diacylglycerol kinase zeta deficiency. *Nat Immunol*. 2003; 4:882–890. [PubMed: 12883552]
- Zhong XP, Shin J, Gorenz BK, et al. Receptor signaling in immune cell development and function. *Immunol Res*. 2011; 49:109–123. [PubMed: 21128010]

Fig. 1. mTOR signaling and its regulation by DGKs. mTOR signaling is mediated by two signaling complexes, raptor-containing mTORC1 and rictor containing mTORC2. DAG, generated by PLCγ1 following TCR engagement, activates the RasGRP1-Ras-Erk1/2 pathway. The pathway plays important roles for mTORC1 and mTORC2 activation in T cells. DGKs negatively control both mTORC1 and mTORC2 signaling by terminating DAG in T cells.